Tevogen Bio Holdings Inc. (TVGN)
Automate Your Wheel Strategy on TVGN
With Tiblio's Option Bot, you can configure your own wheel strategy including TVGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TVGN
- Rev/Share 0.0025
- Book/Share -0.0478
- PB -20.4893
- Debt/Equity -0.6246
- CurrentRatio 0.353
- ROIC 12.1994
- MktCap 181979571.0
- FreeCF/Share -0.0814
- PFCF -13.8462
- PE -4.4735
- Debt/Assets 1.1838
- DivYield 0
- ROE 5.0122
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | TVGN | D. Boral Capital | -- | Buy | -- | $10 | March 4, 2025 |
News
Tevogen Bio's First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned
Published: February 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, aims to set new efficiency standards in the industry, to prove that innovation and cost-effectiveness can coexist. Built with the rising cost of drug development in mind, Tevogen's model aligns with current drug price reform efforts while challenging traditional biotech financing norms to ensure long-term sustainability.
Read More
Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency
Published: February 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, shares a summary of the Company's 2024 financing activity at the one year anniversary of being listed on the Nasdaq exchange.
Read More
Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation's Health and Prosperity
Published: February 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
CEO of Tevogen Bio, Dr. Saadi addresses short selling and its potential impact on the nation's health and prosperity. Reaffirms commitment to shareholders.
Read More
Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, congratulates Robert F. Kennedy Jr.'s as he begins his role at the head of Health and Human Services.
Read More
Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation
Published: February 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), is a clinical-stage specialty immunotherapy biotech company. As the biopharma industry faces increasing competition from international markets and an evolving regulatory landscape, Tevogen Bio's innovative business model positions it as a potential leader in the shift towards cost-efficient, value-driven healthcare.
Read More
About Tevogen Bio Holdings Inc. (TVGN)
- IPO Date 2022-01-05
- Website https://tevogen.com
- Industry Biotechnology
- CEO Ryan H. Saadi M.P.H,
- Employees 18